Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study Multivariable regression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback